

## **Lion Biotechnologies to Host Conference Call to Discuss First Quarter 2017 Financial and Operating Results on Monday, May 1, 2017**

April 24, 2017 1:00 AM ET

SAN CARLOS, CA -- (Marketwired) -- 04/24/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2017 financial and operating results after the close of the U.S. financial markets on Monday, May 1, 2017. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 5:00 p.m. ET.

In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 8895265. The live webcast can be accessed under "News / Events" in the "Investors" section of the Company's website at <http://ir.lbio.com/> or you may use the link: <http://edge.media-server.com/m/p/wfg3mt78>.

A replay of the call will be available one hour after the end of the call on May 1, 2017 until 4:30 p.m. ET on May 31, 2017. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 8895265. The archived webcast will be available for thirty days in the Investors section of Lion Biotechnologies' website at <http://www.lbio.com>.

### ***About Lion Biotechnologies, Inc.***

*Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma. TIL therapy is also being evaluated in clinical trials at the National Cancer Institute, MD Anderson and Moffitt Cancer Center. For more information, please visit <http://www.lionbio.com>.*

### ***Investor Contact:***

***Sarah McCabe***  
***Stern Investor Relations, Inc.***  
***212-362-1200***  
***[sarah@sternir.com](mailto:sarah@sternir.com)***

### ***Media Contact:***

***Alex Ferrara***  
***inVentivHealth Public Relations***  
***212-849-9487***  
***[Alexandra.Ferrara@inventivhealth.com](mailto:Alexandra.Ferrara@inventivhealth.com)***

***Source: Lion Biotechnologies, Inc.***

***Released April 24, 2017***